Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study
Abstract Background Treatment options for advanced nonsquamous non-small cell lung cancer (NSCLC) in the first line include platinum-based doublet therapy with or without bevacizumab. This study examined efficacy outcomes and patient reported outcomes (PROs) in a community oncology patient sample. M...
Main Authors: | Mark S. Walker, William Wong, Arliene Ravelo, Paul J. E. Miller, Lee S. Schwartzberg |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-08-01
|
Series: | Health and Quality of Life Outcomes |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12955-017-0735-4 |
Similar Items
-
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France
by: Taipale K, et al.
Published: (2017-08-01) -
Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non–small‐cell lung cancer
by: Nicole F. Laslett, et al.
Published: (2018-07-01) -
Immunotherapy in the treatment of non-small cell lung cancer (NSCLC) - analysis of epidemiology and cure - review
by: Kinga Ruszel, et al.
Published: (2020-08-01) -
Efficacy and safety of pemetrexed maintenance therapy in advanced non-small-cell lung cancer: a review of phase III studies
by: O I Kit, et al.
Published: (2013-03-01) -
Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study
by: Craig Reynolds, et al.
Published: (2018-05-01)